Russian and ASEAN markets dominated by foreign investment and imports, research shows

20 May 2016

The dominance of foreign investment and imports in Russian and ASEAN (Association of Southeast Asian Nations) pharma markets has been shown by research from UBM.

The conference and media company, which is the leading organizer of CPhl Russia and CPhl South East Asia, has provided an update on trends in the regions following the closing of its events in Moscow and Jakarta.

It organizes events globally and notes that these are two of the fastest growing pharma economies in Asia, something which is increasing demand for foreign investment and has stimulated greater government support into the healthcare system and industry.

This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Try before you buy

Free

7 day trial access

Take a Free Trial

All the news that moves the needle in pharma and biotech
Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
Receive The Pharma Letter daily news bulletin, free forever.

Become a subscriber

£820

Or £77 per month

Subscribe Now

Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
Daily roundup of key events in pharma and biotech.
Monthly in-depth briefings on Boardroom appointments and M&A news.
Choose from a cost-effective annual package or a flexible monthly subscription

The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK